As both OCS and HA show affinity to selectively bind CD44-expressing cells, self-cross-linkable chitosan-HA dialdehyde nanoparticles are used for CD44-targeted siRNA delivery to target oncogene Bcl2 for bladder cancer therapy (76). Here, CD44 is linked to urinary bladder cancer.